Clinical CRO Fang en medicine changed its name to Kun Yu.

Fang En Pharmaceuticals ("Fang En") and its group of companies are now officially renamed Kun Yu Pharmaceuticals ("Kunnong"), which is named ClinChoice Inc. in English.
Kunxuan is a global clinical contract research organization ("CRO") with more than 1,800 clinical research professionals in seven different countries and regions in Asia, North America and Europe.
under the guidance of the new brand strategy, Kun Yu will continue to provide high-quality, full-service clinical research services to pharmaceutical, biotechnology and medical device companies worldwide, with the responsibility of "china-based, global service".
1995, the company has accumulated extensive clinical research experience and regulatory knowledge over the past 20 years, and has conducted business in China, the United States, Europe, India, Japan and the Philippines.
has under gone through a series of mergers and acquisitions and restructurings through his development journey, and has successfully integrated into Fang En Pharmaceuticals, K.L. Consulting and iMed Global.
, as innovations in the life sciences continue to develop, Kun yu will continue to provide high-quality CRO services to global bidders throughout the research and development, registration and commercialization phase.
, the company will actively work with mature and growing companies, relying on a fully functional CRO team to help bidders achieve their local and global strategic goals.
, Chairman and CEO of Kunji Global, said, "Recently we have seen a growing demand for high-quality, high-speed and efficient clinical CRO services from a growing number of life sciences companies around the world.
renamed Kun Yu, we will fully integrate our global team of professionals, develop our professional operational capabilities and regulatory registration knowledge in various countries and regions to better meet the clinical research and development and commercialization needs of various innovative pharmaceutical and device companies.
" Kun Yu's rebranding program, combined with the company's implementation of a series of operational capacity enhancement programs, will strengthen the company's core competitiveness, more effective to provide customers with high-quality clinical research services, and in accordance with ICH standards to support international innovation.
Dan, co-founder of the company, said.
Zhang Dan will continue to serve as Chief Strategy Officer in Kun Yu.
, the former Chairman of FMD K and L, CEO Dr. John D. Balian, and its management team will continue to create value and provide services to their customers under the name-changer ClinChoice.
, Managing Director of Goldman Sachs Direct Investment and a member of the Board of Directors of Kunxuan, said, "As innovative therapies grow globally, CRO's ability to provide efficient and reliable research and development services becomes particularly important."
's unique value proposition combines its understanding of the local market, experience in international drug development, and effective team execution.
believe that the company's strong management team and its ability to execute efficiently will open a new chapter in the development of Kun yu.
" about ClinChoice is a clinical phase CRO dedicated to providing high-quality one-stop service to biomedical and medical device customers, including clinical operations, project management, biostatity, data management, registration services, medical affairs and drug alerting.
has established major clinical delivery centers in China, the United States, Europe, India, Japan and the Philippines, and currently employs more than 1,800 people worldwide, with clinical operations teams in seven countries and regions, including Asia, Europe and North America.
.